Pre-hospital blood product resuscitation for trauma:a systematic review by Smith, Iain M et al.
 
 
Pre-hospital blood product resuscitation for trauma
Smith, Iain; James, Robert H; Dretzke, Janine; Midwinter, Mark
DOI:
10.1097/SHK.0000000000000569
License:
None: All rights reserved
Document Version
Peer reviewed version
Citation for published version (Harvard):
Smith, IM, James, RH, Dretzke, J & Midwinter, MJ 2016, 'Pre-hospital blood product resuscitation for trauma: a
systematic review', Shock. https://doi.org/10.1097/SHK.0000000000000569
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked for eligibility: 23/05/2016. This is a non-final version of an article published in final form in Smith, Iain M., et al. "Pre-Hospital Blood
Product Resuscitation for Trauma: a Systematic Review." Shock (2016).
doi: 10.1097/SHK.0000000000000569
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
1 
 
Pre-hospital blood product resuscitation for trauma: a systematic review 
Iain M Smith1,2,4, Robert H James3,5,6, Janine Dretzke1,7 and Mark J Midwinter1,2 
 
Affiliations 
1NIHR Surgical Reconstruction & Microbiology Research Centre, University of Birmingham, UK 
Academic Departments of 2Military Surgery & Trauma and 3Military Emergency Medicine, Royal 
Centre for Defence Medicine, ICT Centre, Birmingham Research Park, Edgbaston, Birmingham, B15 
2SQ, UK 
4205 (Scottish) Field Hospital, 130 Whitefield Road, Govan, Glasgow, G51 2YE, UK 
5East Anglian Air Ambulance, Hangar E, Gambling Close, Norwich Airport, Norwich, NR6 6EG 
6Ministry of Defence Hospital Unit Derriford, Derriford Hospital, Brest Rd, Plymouth, PL6 8DH, UK 
7Institute of Applied Health Research, University of Birmingham 
 
Corresponding Author 
Surg Capt Mark Midwinter CBE MD FRCS RN, Deputy Director, National Institute for Health 
Research, Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital, 
Birmingham, B15 2GW, UK, Queen Elizabeth Hospital, Birmingham, B15 2GW 
Email: Mark.Midwinter@uhb.nhs.uk 
Phone: +44 (0) 751 541 9965 
 
Support: No financial support was received in relation to this study 
2 
 
 
Running Head: Pre-hospital blood products for trauma 
Abstract 
Introduction: Administration of high ratios of plasma to packed red blood cells is routine practice 
for in-hospital trauma resuscitation. Military and civilian emergency teams are increasingly 
carrying pre-hospital blood products (PHBP) for trauma resuscitation. This study systematically 
reviewed the clinical literature in order to determine the extent to which the available evidence 
supports this practice. 
Methods: Bibliographic databases and other sources were searched to July 2015 using keywords 
and index terms related to the intervention, setting and condition.  Standard systematic review 
methodology aimed at minimising bias was used for study selection, data extraction and quality 
assessment (protocol registration PROSPERO: CRD42014013794). Synthesis was mainly narrative 
with random effects model meta-analysis limited to mortality outcomes.  
Results: No prospective comparative or randomised studies were identified. Sixteen case series 
and eleven comparative studies were included in the review. Seven studies included mixed 
populations of trauma and non-trauma patients. 25/27 studies provided only very low quality 
evidence. No association between PHBP and survival was found (OR for mortality: 1.29, 95% CI: 
0.84–1. 96, P=0.24). A single study showed improved survival in the first 24 hours. No consistent 
physiological or biochemical benefit was identified, nor was there evidence of reduced in-hospital 
transfusion requirements. Transfusion reactions were rare, suggesting the short-term safety of 
PHBP administration. 
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Conclusions: While PHBP resuscitation appears logical, the clinical literature is limited, provides 
only poor quality evidence and does not demonstrate improved outcomes. No conclusions as to 
efficacy can be drawn. The results of randomised controlled trials are awaited. 
Keywords 
Wounds and Injuries; Haemorrhage; Emergency Medical Services; Blood Component Transfusion; 
Erythrocyte Transfusion; Plasma; Meta-Analysis; Military Medicine   
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Introduction 
Liberal blood product resuscitation has probably contributed to improved casualty survival in 
recent conflicts (1, 2). Early administration of plasma in high ratios to packed red blood cells 
(PRBC) is characteristic (3). The reintroduction of military pre-hospital blood product (PHBP) 
resuscitation was a logical evolution and is increasingly mirrored in civilian practice. However, the 
evidence supporting plasma rich resuscitation is limited to systematic reviews of predominantly 
retrospective, observational studies (4, 5). A Cochrane review of plasma in massive transfusion is 
yet to be published (6), while a review of plasma transfusion in the critically ill failed to identify 
any relevant randomised studies (7). A recent observational study (8) associated early plasma 
administration with improved 30 day survival (9). However, the PROPPR trial found that despite 
achieving earlier haemostasis, resuscitation with plasma, platelets and PRBC in 1:1:1 ratios did not 
improve overall survival compared to 1:1:2 (10). 
 
PHBP were used during the Vietnam War (11). with civilian pre-hospital PRBC administration 
reported in 1985 (12). In 2008, plasma and PRBC were added to the capabilities of the British 
military’s Medical Emergency Response Team (Enhanced) (MERT(E)) (13). Other nations have 
implemented similar strategies (14, 15). Retrieval by MERT(E) is associated with improved survival 
after major injury (16). However blood product administration is not unequivocally benign; in 
addition to transfusion reactions, increasing blood product receipt after trauma has been 
independently associated with ARDS (17), multi-organ failure (18) and mortality (19-21). This 
suggests a context-specific balance of risks and benefits. In addition, widespread implementation 
of PHBP resuscitation (especially plasma) in civilian practice is challenging. Only 4% of US and UK 
donor pools are universal (group AB) plasma donors and the shelf-life of thawed plasma is only 24 
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hours. Nonetheless, various PHBP combinations have been delivered with minimal wastage (22-
28). 
 
The aim of this systematic review was to determine the extent to which PHBP resuscitation for 
trauma is supported by clinical evidence.  
 
Methods 
The study was registered with PROSPERO (CRD42014013794), was conducted according to the 
published protocol (29) and is reported according to PRISMA guidelines (30) (Supplementary 
Digital Content 1, PRISMA Checklist). Relevant studies were sought from bibliographic databases 
(monthly searches to July 2015) and other relevant sources; see protocol (30) for full details and 
Medline search strategy (see also Text, Supplementary Digital Content 2, EMBASE search strategy). 
Standard systematic review methodology aimed at minimising bias was used for study selection 
and data extraction. Studies were eligible if they evaluated blood products (case-series) or 
compared these to other resuscitative fluids (controlled studies); were in patients aged ≥ 16 years 
with traumatic haemorrhage; and were conducted in a military or civilian setting.  There was no 
restriction by outcome. Data not included in published manuscripts or abstracts were sought from 
the relevant authors. 
 
Ten studies which met selection criteria were not taken forward for analysis (Table, 
Supplementary Digital Content 3, relevant studies excluded). Seven reported no patient outcomes. 
Three reported PHBP as an inconsistent component of a care bundle; no association between 
PHBP receipt and outcomes could be determined. 
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Risk of bias assessments were made using the Newcastle-Ottawa Scale (31) for comparative 
studies. Case series and uncontrolled before-and-after series were assessed with appropriate tools 
(32, 33). The quality of evidence provided by each study was reported using the GRADE method 
(34). GRADE allows ratings to be upgraded due to strengths or downgraded due to limitations. In 
this review studies were downgraded for important disparities between cohorts, lack of control for 
injury burden and significant loss-to-follow-up. Given the inherent limitations of observational 
studies, merely meeting most or all design quality criteria was insufficient to merit upgrading; no 
studies were upgraded. 
 
Two cohort studies reported additional subgroup analyses (35-i, 36-i). One reported matched 
patients and primary retrievals (patients transported directly from the incident scene to the 
trauma centre) (35-ii, 36-iii). The second reported primary retrievals (36-ii). Data from either main 
or sub-studies were included as appropriate and are indicated accordingly. 
 
Due to the disparate nature of populations, interventions and outcomes, only limited meta-
analysis was possible. Consequently a narrative synthesis of the available evidence was 
constructed. Evidence for the following outcomes was considered: long term mortality (30 days or 
in-hospital), early mortality (pre-hospital or at 24 hours), in-hospital transfusion requirements, 
vital signs and biochemical/haematological indices up to and at Emergency Department arrival. 
 
Pooled estimates of mortality were calculated using inverse weighting and mixed models to reflect 
heterogeneity between studies. Meta-analysis of 30 day/index admission survival was performed 
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using the Mantel-Haenszel method with a random effects model. The principal summary statistic 
was the Odds Ratio. Statistics were computed with Review Manager 5.3 (Nordic Cochrane Centre, 
Copenhagen, Denmark) and R 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria). 
 
Results 
Study selection is shown in Fig. 1. Sixteen case series and eleven comparative studies (1 case 
control, 10 retrospective cohort) were included. Nine studies considered military trauma patients. 
Eighteen considered civilian patients, of which seven pooled trauma and non-trauma patients. The 
aims of case series were varied; frequent themes were feasibility, process description or 
characterisation of PHBP-recipients. Comparative studies examined associations between PHBP 
receipt and physiological parameters or clinical outcomes. 
 
Both arms of one cohort study (37) formed part of a case series (38) which formed one arm of a 
second cohort study (39). As each study reported different aspects of PHBP resuscitation, each 
was considered individually. Only the final study was included in summary measures. One military 
study (40) contained an intervention cohort drawn from a larger case series (41). 
 
Tables 1 and 2 summarise the various study and population characteristics. For interventions and 
important differences between cohorts see (Table, Supplementary Digital Content 4, Study 
Interventions and Differences). In total, 1080/4714 (23%) patients in comparative studies received 
PHBP; 2668 PHBP-recipients were reported in case series, of whom 1463 (55%) had sustained 
trauma. 
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No blinded or randomised studies were identified - other than one prospective case series, all 
were retrospective observational studies. Only two studies provided more than “Very Low” quality 
evidence (see Table, Supplementary Digital Content 5, Risk of bias assessments). Most 
comparative studies were limited by differences between groups (injury burden, additional in-
transit interventions or in-hospital treatment) without control by case matching or statistical 
methods. Common limitations of case series included lack of a clear research question, pooling of 
trauma and non-trauma patients, small numbers and lack of robust clinical outcome measures. 
 
Long-term Mortality 
Long-term mortality amongst PHBP-recipients varied from 8% to 52% (Fig. 2A). This analysis 
included unpublished absolute survival data for one cohort study (35-i) (J. Brown. 2015, pers. 
comm. 08 June). One study reported 67% mortality amongst six subjects, but was excluded from 
analysis due to 60% loss-to-follow-up (15). Early studies reported loss to follow-up of 18% (12) and 
20% (14). Later studies either minimised such losses through design or improved record keeping or 
(particularly when published in abstract) had insufficient information to allow loss to follow-up to 
be assessed. In studies from military operations in Afghanistan survival of non-coalition casualties 
was reported up to point of transfer to host nation medical facilities (up to 47% of study 
population). Significant post-transfer mortality was considered unlikely as patients were only 
transferred once in established recovery (42, 43). The pooled mortality estimate of 32% (95% CI: 
26% - 38%) exceeds the 23% mortality reported in profoundly hypotensive (SBP<90mmHg) trauma 
patients treated without PHBP (44, 45) and provides no obvious evidence of benefit. Meta-analysis 
of uncorrected mortality data was performed, using matched data where available. PHBP receipt 
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was not associated with reduced mortality (OR for mortality: 1.29, 95% CI: 0.84–1.96) (Fig. 3A). 
Heterogeneity was substantial (I2 = 63%). Limiting the meta-analysis to matched studies provided 
no evidence of benefit (Fig. 3B). Only three studies reported mortality adjusted for confounders 
(Fig. 4A) (35, 36, 46). These were not combined statistically.  
 
Matched cohort studies (35-ii, 40) reported markedly lower mortality amongst PHBP-recipients 
than the unmatched PHBP cohorts from which they were drawn (35-i, 41). This may indicate 
tasking of more capable assets to casualties with more severe injuries, resulting in fewer non-
recipient matches as injury burden increases. If so, matched studies will underestimate mortality 
amongst PHBP-recipients but may also underestimate the potential effect size of PHBP due to the 
exclusion of patients at greater risk of death, amongst whom a survival benefit might be more 
evident. 
 
Seven cohort studies reported mortality (Fig. 3A). Only one study found an association between 
PHBP receipt and absolute survival (40), while three reported increased absolute mortality (35-i 
(unpublished data), 37, 46). However, the mortality difference reported in the first of these (35-i) 
was lost when only matched patients were considered (35-ii). 
 
An absolute mortality reduction of 11% was reported amongst battlefield casualties matched by 
injuries to historical controls from the same facility (40). Acknowledged confounders included 
limited in-hospital plasma and PRBC transfusions received by both cohorts - 75% of non-recipients 
received no blood products after hospital arrival. Transfusion practice at this facility became more 
liberal over time (47); reflected in larger in-hospital transfusion volumes received by the later 
10 
 
PHBP cohort. Other differences included shorter transport times, more frequent pre-hospital 
airway support, more tranexamic acid and higher in-hospital transfusion ratios (FFP:PRBC 1:1 vs. 
0.46:1) amongst PHBP recipients.  Recent data from this facility show a stepwise annual survival 
improvement at all levels of injury (2), suggesting that comparison with this historical cohort will 
have introduced significant confounding.  
 
A contemporaneous cohort study of battlefield casualties with major trauma (New Injury Severity 
Score≥16) treated at the above facility (46) found an independent association between PHBP 
receipt and  mortality in multivariate analysis. However, marked differences in injury mechanisms, 
wounding patterns and especially injury burden probably defied statistical correction. These 
military studies were limited by frequent non-availability of pre-hospital vital signs, hence pre-
transfusion physiological status could not be assessed.  
 
Significant baseline differences are found in two smaller civilian cohort studies (37, 48). The 
former compared 50 injured pre-hospital PRBC recipients with 9 patients who also received 
plasma. Indications for plasma transfusion included known pharmaceutical anticoagulation. 
Plasma recipients had a pre-transfusion INR of 2.6 (vs. 1.5 amongst non-recipients) and this 
remained higher at hospital arrival. In-hospital treatment also differed; plasma recipients received 
transfusion ratios closer to 1:1 and less crystalloid. Plasma recipients had a higher Trauma Injury 
Severity Score (TRISS)-predicted mortality and over 50% died, despite more aggressive blood 
product resuscitation. The latter study (in subjects well matched by injury burden) found no 
survival difference, though PHBP-recipients had longer pre-hospital times (mean: 30min) than 
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non-recipients (mean: 12min) (48). Neither study was adequately powered to detect a mortality 
difference. 
 
The earliest matched cohort study identified that PHBP-recipients received almost four times 
more pre-hospital crystalloid, were intubated more frequently and received 50% more PRBC 
during in-hospital resuscitation than non-recipients (49). No survival benefit was found. The 
authors speculated that PHBP “may have compensated for…longer transport times and possibly 
more gravely injured patients”. 
 
The most robust studies to date are two contemporaneous cohort studies (35, 36). The first 
compared 50 blunt trauma patients who received a median of 1.3u pre-trauma centre (PTC) PRBC 
to 1365 non-recipients. Despite similar injury burdens, unadjusted mortality in PHBP-recipients 
was 28% vs. 16% in non-recipients (P=0.02) (J Brown 2015, pers. comm. 08 June). PHBP recipients 
were more often secondary transfers (48%) than non-recipients (4%)—introducing a high risk of 
selection bias due to the probability that more “unavoidable” early deaths were included amongst 
non-recipients. As in military studies, PHBP-recipients were managed more aggressively, receiving 
2.5 times more PTC crystalloid, more in-hospital PRBC and more platelet transfusions. However, in 
regression analysis PHBP receipt was associated with reduced 30 days mortality. 35 PHBP-
recipients were propensity matched with 78 non-recipients. PHBP-recipients were less frequently 
hypotensive at hospital arrival and the median PRBC transfusion was 69% greater than for non-
recipients. Regression analysis again found an association between PHBP-receipt and improved 30 
day survival. However, whether statistics can correctly adjust for very different transfusion 
strategies in a relatively small study is uncertain. In contrast, the same group’s larger study 
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comparing 240 PHBP-recipients to 480 non-recipients, transported by a single service to one 
trauma centre, found no overall survival benefit from PTC PRBC (36-i). 
  
Early mortality 
Six case series reported pre-hospital mortality (23, 25, 50-53). Three cohort studies and one case 
series reported 24-hour mortality (Fig. 2B) (35-37, 54). Two of the latter reported adjusted odds 
ratios, including three subgroup analyses (Fig. 4B) (35, 36). These suggest an effect on early 
mortality, but are limited by the small proportion of PHBP-recipients. Of note, mortality amongst 
PHBP-recipients is almost 50% greater when only primary retrievals are considered (36) suggesting 
that these are a different population from secondary transfers. This may lead to marked selection 
bias when proportions of primary retrievals and secondary transfers differ between cohorts (35-i). 
However, early survival benefits remained when matched cohorts containing similar proportions 
of secondary transfers were considered (35-ii). Statistical significance was lost when primary 
retrievals alone were considered (35-iii). 
 
In-hospital transfusion 
Six studies reported in-hospital blood product resuscitation (Fig. 5) (35-37, 40, 46, 49). Four studies 
matched by injury burden (35, 36, 40, 49), two did not (37, 46). In military studies PHBP-recipients 
received more in-hospital transfusions (40, 46). The former reflects changes in transfusion practice 
over time, whilst the latter studies are confounded by differences in injury. No study provided 
evidence of reduced in-hospital transfusion requirements.  
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Vital Signs 
Four case series report an increase in SBP (12, 53, 54) or decrease in HR or Shock Index (54, 55) 
associated with PHBP receipt. Amongst military casualties PHBP receipt was associated with a 
significantly greater correction in Shock Index (56). However, PHBP-recipients were significantly 
more haemodynamically compromised prior to transport, thus had greater scope for correction. 
Consequently, reporting absolute correction biases the study in favour of PHBP. Two-thirds of 
eligible patients were excluded due to non-availability of pre- and post-transfusion vital signs. This 
may indicate selection bias if vital signs were unrecordable or interventions prioritised in the 
sickest patients. 
 
In a matched subgroup analysis pre-hospital hypotension was more common in PHBP-recipients 
but was less common at hospital arrival (35). However, in a larger study, although pre-hospital SBP 
were similar, PHBP-recipients were more frequently shocked on arrival (36). The final civilian 
cohort study identified no difference in haemodynamic changes between PHBP-recipients and 
non-recipients (48). In a case-control study, patients hypothermic at ED arrival were more likely to 
have received PHBP (57). However the significance of this is unclear, as crystalloids were warmed 
before administration whereas PRBC were not (F. M. von Recklinghausen (2015) pers. comm. June 
23). Collectively, the published data provide no evidence that PHBP improves physiology 
compared to crystalloids. 
 
Coagulopathy and Acid-Base 
Two overlapping studies report correction of predominantly warfarin-related anticoagulation with 
pre-hospital plasma. In a case series of mixed trauma and non-trauma patients, INR reduced from 
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4 to 2 (38). In a cohort study—whose pooled subjects formed part of that series—greater absolute 
correction (INR 2.6 to 1.6) was seen in plasma recipients than non-recipients (INR 1.5 to 1.3) (37). 
However, pharmaceutical anticoagulation is not analogous to trauma-induced coagulopathy (TIC) 
thus these papers demonstrate only that plasma-mediated reversal of pharmaceutical 
anticoagulation can be delivered pre-hospital and should not be extrapolated to suggest a benefit 
in the treatment of trauma induced coagulopathy (TIC). In blunt trauma patients, PHBP were 
associated with reduced odds of TIC, however the PHBP group also received greater volumes of 
crystalloid (35). The association was not found in the same group’s larger study in which both 
cohorts received comparable crystalloid volumes (36). It is possible that greater crystalloid loading 
reduced TIC-inducing hypoperfusion. In military data, PHBP receipt was independently associated 
with TIC (46) but this probably reflects vastly greater tissue disruption in PHBP-recipients. 
 
PHBP receipt has been associated with greater acidosis at hospital arrival compared to non-
recipients with comparable injury burdens (48). PHBP-recipients had mean flight times of 34min 
vs. 12min for non-recipients. This provided greater opportunity for PHBP administration, but 
potentially longer uncontrolled bleeding. In contrast, PHBP receipt was associated with a non-
significant trend to lower serum lactate concentration when pre-hospital times were less than 150 
minutes (58). However, no details of study size or blood products administered were available. 
 
Adverse events 
Amongst 759 PHBP-recipients in studies which specifically reported presence or absence of 
transfusion reactions (12, 14, 25, 36, 38, 55, 59), only three possible reactions were noted. One 
patient suffered transient shortness of breath after infusion of 5L crystalloid and 900ml PRBC (12), 
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although this was probably secondary to volume overload, one patient developed a “fine [truncal] 
rash” following one unit of PBRC (14) and one patient had a reaction during a subsequent in-
hospital transfusion (36). These studies suggest that PHBP receipt is associated with a minimal risk 
of transfusion-related adverse events. 
 
Discussion 
PHBP resuscitation is increasingly employed to try to reduce the 23% mortality amongst 
hypotensive trauma patients (44, 45). However, provision of universal PHBP components to all 
trauma networks involves substantial clinical, logistical and fiscal costs. In this first systematic 
review of the topic, we evaluated the clinical evidence around PHBP for trauma. We identified 27 
observational studies which reported relevant clinical outcomes. 26/27 were retrospective. 25/27 
provided very poor quality evidence. Common limitations were the lack of a control group or a 
control group which differed significant from PHBP-recipients. Most comparative studies were too 
small to permit adjustment for confounders. Studies frequently pooled primary retrievals with 
secondary transfers, despite these being distinct populations. While PHBP resuscitation is 
achievable with minimal wastage of universal donor components, and with short-term safety, no 
more than low quality evidence supports this as a “standard of care”. This review did not identify 
an overall survival benefit. Evidence for improved survival at 24 hours is derived from only two 
observational studies and, even if a true effect, may not translate to improved long-term 
outcomes. 
 
Differences between patients and/or treatment pathways further limited the studies considered in 
this review.  Even when subjects were matched, PHBP-recipients received more in-hospital 
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transfusions. Consequently, even where associations between PHBP and improved survival are 
found after statistical correction, this improvement cannot be confidently attributed to PHBP 
receipt.  
 
The available clinical data shows no evidence that PHBP reduces in-hospital transfusion. This is 
consistent with recent animal modelling of pre-hospital resuscitation (60). Although TIC was 
reduced by blood products in various ratios compared to saline, transfusion requirements over the 
subsequent 150 minutes of “hospital” resuscitation were similar in all groups. Similarly, a previous 
animal model of uncontrolled splenic haemorrhage showed that whilst Hextend increased blood 
loss compared to blood products—potentially reflecting the previously reported exacerbation of 
TIC produced by hetastarches (61)—there was no difference in post-resuscitation blood loss 
between blood product resuscitation and Hartmann’s solution (62). The combination of lyophilised 
plasma and PRBC in a 1:1 ratio has been shown to reduce total blood loss in a swine polytrauma 
model compared to both plasma alone and to 1:1 FFP:PRBC resuscitation (63). Short-term survival 
was not improved by resuscitation with blood products compared to crystalloid. Long-term animal 
survival studies would be ethically challenging and have not been performed. 
  
As with our findings from the clinical literature, a swine model of PHBP resuscitation did not 
improve acid-base status. A non-significant trend to less extreme maxima for serum lactate and pH 
amongst “haemostatically resuscitated” animals was found, however there were fewer than ten 
animals per group (60). In other animal studies, neither plasma lactate concentration (63) nor 
acid-base status (62) has been influenced by different blood product ratios. Any metabolic benefit 
from PHBP remains uncertain. 
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Strengths and Limitations 
The searches for this review were not restricted by language nor by date and included all major 
citation databases, specialist resources and reference lists from included studies. It is unlikely that 
material which would significantly change the findings has been overlooked. 
 
The most significant weakness of the study is the low quality of evidence on which the review 
could draw. Consequently, no conclusions about the efficacy of PHBP resuscitation can be drawn. 
The extent to which this review makes use of “grey literature” reflects the poor state of evidence 
in this area. This material has not been subjected to the same degree of peer review as that in 
published papers, but is nonetheless recognised as being an essential component of a systematic 
review (64). 
 
These considerations limited the possible statistical syntheses to unadjusted mortality alone, with 
no indication identified of improved long term survival after PHBP receipt. However the marked 
differences between the populations in included studies render this finding tenuous. These 
difficulties are consistent with previous reviews of blood product resuscitation for trauma (65, 66). 
Meta-analysis produces not only an estimate of overall effect size, but a measure of heterogeneity 
from which the consistency of the literature can be assessed. In meta-analysis of both unmatched 
and matched studies, heterogeneity was present and significant, demonstrating the degree of 
uncertainty which exists about a measurable benefit of PHBP resuscitation. 
 
This review considered both military and civilian studies. The validity of extrapolating from studies 
of predominantly younger, massively traumatised males to the civilian population is questionable. 
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However, the inclusion of military case series illustrates the marked change in resuscitation 
practice over the last decade and thus further factors which must be considered when interpreting 
the existing literature. Transfusion criteria used by the Israeli military initially required 2L 
crystalloid administration prior to administration of PRBC, with casualties receiving an average of 
4.4L of pre-hospital crystalloid (14). Lyophilised plasma has now replaced crystalloid in Israeli 
retrieval missions (67), such that “crystalloid infusion was minimised” (15). Similar practices have 
been adopted by the UK military, with casualties retrieved by MERT(E) in Afghanistan receiving up 
to 4u PRBC and 4u plasma (41) with crystalloid minimised (3). This is borne out in data examined in 
this review (46). In contrast, civilian studies continue to include failure to respond to 2L 
intravenous crystalloid as an indication for PHBP. This is despite good quality evidence that 
aggressive clear fluid administration increases mortality and morbidity after penetrating trauma 
(68). Pre-hospital cannulation (as a surrogate for fluid administration) was associated with greater 
mortality in every patient subgroup examined in a registry study, other than those with Injury 
Severity Scores <9 (69), while more than 1L of pre-hospital fluid has been shown to be an 
independent risk factor for death in patients without severe traumatic brain injury (70). High ratios 
of crystalloid to PBRC given in-hospital increase morbidity (71). Whether PHBP are associated with 
similar volume effects is unknown. It is possible that the negative impact of crystalloid loading 
prior to PHBP administration has masked benefit from PHBP in many studies to date. 
 
Safety 
Very few PHBP-related adverse events were identified, implying transfusion safety. However, 
blood transfusions supress the immune system and are associated with a stepwise increase in 
infectious complications for each unit of PRBC transfused, starting with single unit transfusions 
(72). Similarly, a dose-response relationship exists between transfusion and development of multi-
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organ failure (73). This is a concern given the frequency with which patients in this review received 
PHBP but little or no in-hospital transfusion, calling into question their need for PHBP transfusion. 
No study in this review associated PHBP with reduced in-hospital transfusion. However, if 
administered inappropriately liberally, PHBP may lead to excess morbidity. 
 
In order to address these various questions, four randomised clinical trials and one cohort study 
comparing various combinations of blood products and crystalloid are underway (see Table, 
Supplementary Digital Content 6, ongoing studies). If PHBP trauma resuscitation is beneficial, 
universal provision should be advocated. However, robust evidence is required to justify the 
clinical, logistical and financial costs of making PHBP “standard care”. This review demonstrates 
the lack of such evidence and makes ongoing support for these studies imperative. 
 
Military and expedition settings require the consideration of factors specific to austere 
environments. Although evacuation times in recent operations have typically been short, future 
conflicts may require prolonged pre-evacuation field and en-route care. These timelines may 
necessitate PHBP support. Data collection on future operations will be essential to establish the 
place of PHBP in “Remote Damage Control Resuscitation” 
 
Conclusions 
The literature reporting PHBP for trauma resuscitation is contradictory and provides only poor 
quality evidence. Evidence-based conclusions to guide practice cannot be drawn. While PHBP 
resuscitation appears logical the potential harms of this practice must be recognised. More 
rigorous evidence of benefit is required to justify universal adoption. Whether PHBPs improve 
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survival despite these competing risks is unknown. The only satisfactory way to answer this 
outstanding question of benefit from PHBP-based resuscitation for major traumatic haemorrhage 
is by randomised controlled trials.   
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Figure 1. PRISMA diagram for selection of included studies. 
†including studies only available in abstract. ‡trial design or authors blinded to allocations. 
 
Figure 2. Mortality amongst PHBP-recipients. A) Overall B) Within 24h 
Grey bars: case series. Black bars: cohort studies. Solid bars: Trauma patients.  Hashed bars: 
studies including both trauma and non-trauma patients. Unfilled bars: subgroup analyses or 
patients drawn from a larger series, published separately (not included in estimation of mortality). 
Pooled estimate of mortality shown with 95% confidence interval. 
 
Figure 3. Meta-analysis of unadjusted risk of mortality. 
A) All comparative studies B) Studies with matched cohorts 
 
Figure 4. Forest plot of adjusted mortality. A) Overall B) at 24 hours 
Data shown for adjusted Odds Ratios, other than Brown et al (2015) (35) which shows Hazard 
Ratio. 
: data from main study : data from subgroup analysis 
 
Figure 5. In-hospital transfusion requirements for A) PBRC and B) plasma. O’Reilly et al (2014) (40) 
and Smith et al (2014) (46) reported total transfusion data from primary receiving hospital. Brown 
et al (2015) (35, 36) and Kim et al (2012) (37) reported transfusion data within 24h of admission. 
Data shown as median (IQR) except for Kim et al (2012) (37) (median only). Δ: median transfusion 
for PHBP-recipients, X: median transfusion for non-recipients. Price et al (1999) (49) also reported 
statistically significantly greater in-hospital transfusion volumes for PHBP-recipients (mean 1414ml 
(SD: 1660ml)) vs. non-recipients (1007ml (SD: 935ml)). 
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Table 1: Case Series – Study and Patient characteristics 
Authors 
 
Paper/ Abstract 
Timing Purpose of study 
Context1 
Trauma / Mixed 
(Secondary 
Transfers) 
Patients 
in study 
(%male) Age Mechanism of injury Injury Burden Intervention 
Dalton 
(1993) (12) 
Portland, OR, USA 
Full Text 
(Retrospective) 
demonstrate safety Civilian Trauma 
(unknown) 
112 
(unknown) 
 RTA: 81 (72%) 
Penetrating: 16 (14%) 
Other: 15 (13%) 
mean ISS: 32 PBRC:416ml 
[R:100-1250] 
Berns and Zietlow. 
(1998) (59) 
Rochester, MN, USA 
Full Text 
(Retrospective) 
describe protocols and 
experience 
Civilian Mixed 
(Trauma: 48%) 
(Transfers: 91%) 
94 
(75%) 
51-60 
(21-30 to 
71-80) 
Unknown Unknown “average” 2u PRBC 
Prause et al. 
(1999) (52) 
Graz, Austria 
Full Text 
(Retrospective) 
Description of process Trauma 
(Transfers: 0%) 
 
26 
(unknown) 
? Unknown Polytrauma: 12 
Amputations: 4 
Torso trauma: 6 
Craniocerebral: 2 
Unspecified: 2 
Not specified 
Badjie et al. 
(2012) (38) 
Rochester, MN, USA 
Abstract 
(Retrospective) 
evaluate the impact of using 
thawed plasma on board 
Civilian Mixed 
(Trauma: 48%) 
(Transfers: 91%) 
81 
(48%) 
 Unknown Unknown PBRC: 3 units 
Plasma: 2 units 
Higgins et al. 
(2012) (55) 
Portland, ME, USA 
Full Text 
(Retrospective) 
describe the PHBP experience, 
focussing on protocol compliance, 
provider safety, patient outcomes 
and transfusion complications. 
Civilian Mixed 
(Trauma 71%) 
(Transfers: 68%) 
45 
(unknown) 
 Unknown Unknown PBRC: mean 1.4u 
(SD: 0.23u) 
Chew et al. 
(2013) (51) 
Victoria, Australia 
Abstract 
(Retrospective) 
report PHBP supply procedures to 
audit supply procedures and use 
Civilian Mixed 
(Trauma >78%) 
(Transfers: 12%) 
59 
(58%) 
Median 37 
 Range:  
16-81 
RTC: 46 (78%) 
Other trauma or 
medical: 13 (22%) 
Unknown PBRC: 2u (IQR: 2-4u) 
Mena-Munoz et al. 
(2013) (74) 
Pittsburgh, PA, USA 
Abstract 
(Retrospective) 
characterise PHBP-recipients Civilian Mixed 
(Trauma 25%) 
(Transfers: 92%) 
1441 
(unknown) 
? Unknown Unknown Up to 2u PBRC 
Sherren et al. 
(2013) (25) 
Sydney, Australia 
Abstract 
(Retrospective) 
Unclear Civilian Trauma 
(Transfers: 0%) 
147 
(69%) 
34.5 
 (22-52) 
Blunt: 121 (82%) 
Penetrating: 9 (6%) 
Other: 17 (12%) 
RTS: 5.967 
(4.083-6.904) 
PBRC: 3u 
(Range: 1-6u) 
Weaver et al 
(2013) (23) 
London, UK 
Abstract 
(Prospective) 
examine the impact of on-scene 
blood transfusion for seriously 
injured patients 
Civilian Trauma 
(Transfers: 0%) 
50 Mean : 35 Unknown Unknown PRBC: mean 2.8u 
Bodnar et al. 
(2014) (50) 
Queensland, 
Australia 
Full Text 
(Retrospective) 
describe the characteristics, 
clinical interventions and 
outcomes of PHBP-recipients 
Civilian Trauma 
(Transfers: 0%) 
71 
(79%) 
39.6 
(SD=16.7) 
Blunt: 52 (73%) 
Penetrating: 19 (27%) 
ISS: 32.11 (18.19) 
RTS: 4.7 (2.73) 
TRISS: 0.573 (0.396) 
PBRC: mean 1.8u 
(SD: 0.7u) 
Sunde et al. 
(2015) (53) 
Bergen, Norway 
Full Text 
(Retrospective) 
evaluate feasibility of introducing 
FDP and PRBC 
Civilian Mixed  
(Trauma 56%) 
(Transfers: 0%) 
16 
(88%) 
Range 
 23-51 
Blunt: 5 (31%) 
Penetrating: 4 (25%) 
Non-Trauma: 7 (44%) 
Unknown FDP: 200ml 
(Range: 100-200ml) 
PBRC “given to 4 patients” 
Barkana et al. 
(1999) (14) 
Israel 
Full Text 
(Retrospective) 
"characterise aspects" of PHBP 
use "evaluate potential effects on 
morbidity & mortality" 
Military Trauma 
(Transfers: 0%) 
40 
(unknown) 
Range: 
18-37 
Blast: 19 (47.5%) 
Penetrating: 12 (30%) 
Blunt: 9 (22.5%) 
ISS: 18 
(11.5-25) 
PRBC: 1u (IQR: 1-2) [R: 1-4] 
 
 
Malsby et al. 
(2013) (15) 
Afghanistan 
Full Text 
(Retrospective) 
Process refinement Military Trauma 
(Transfers: 0%) 
15 
(100%) 
 Explosive: 13 (87%) 
GSW: 2 (13%)  
unknown Median 1u blood products          
(IQR: 0.5-1.5u) [R: 0-2] 
(Various combinations of 
PHBP administered) 
Glassberg et al. 
(2013) (67) 
Israel 
Full Text 
(Retrospective) 
Description of initial experience 
with pre-hospital lyophilised 
plasma 
Military Trauma 
(Transfers: 0%) 
10 
(unknown) 
 Penetrating: 8 (80%) 
Other 2 (20%) 
ISS: 19 
(17.5-23.5) 
FDP: 1.5u (IQR: 1-2) 
PRBC transfusion implied 
O'Reilly et al. 
(2014) (41) 
Afghanistan 
Full Text 
(Retrospective) 
Description of initial experience 
with PHBP 
Military Trauma 
(Transfers: 0%) 
310 
(97%) 
24 
(21-27) 
Explosive: 226 (73%) 
GSW: 80 (26%) 
Blunt: 3 (1%) 
Burn: 1 (0.3%) 
mISS 20 (16-29) 
mNISS 29 (18-48) 
PBRC: 2u (IQR: 1-2) 
[Range: 0-4] 
Plasma: 2u (IQR: 1-2) 
[Range: 0-4] 
Chen 
(2014) (75) 
Israel 
Abstract 
(Retrospective) 
Unclear Military Trauma 
(Transfers: 22%) 
90 
(80%) 
28 
Range: 
12-60 
Explosive: 20 (22%) 
RTC: 26 (29%) 
GSW: 32 (36%) 
Stab: 5 (5%) 
Other: 7 (8%) 
unknown PRBC: mean 1.2u 
392ml (SD: 322) 
Powell-Dunford et al. 
(2014) (54) 
Afghanistan 
Full Text 
(Retrospective) 
Description of process risk 
mitigation 
Military Trauma 
(Transfers: 0%) 
61 
(98%) 
24  
(20-28) 
Explosive: 45 (74%) 
GSW: 16 (26%) 
unknown PBRC: 1u (IQR: 1-1) 
[Range: 1-2] 
Plasma: 0u (IQR: 0-0) 
[Range: 0-1] 
FDP: Freeze Dried Plasma. 
mISS and mNISS: ISS and NISS derived from the military edition of the Abbreviated Injury Scale (2005) 
¹"military": casualties of armed conflict. 
 
 
 
 
Table 2. Comparative Studies: Study and Patient Characteristics (all trauma except for Badjie et al. (2013)) 
Authors 
Study Type 
Paper/ Abstract 
(Timing Context) Purpose of study 
Group 
(Secondary 
transfers) 
Patients in 
study arm 
(% male) Age Mechanism of injury Injury Burden Intervention 
Price et al. 
(1999) (49) 
Portland, OR, USA 
Matched Cohort 
Abstract 
(Retrospective 
Civilian) 
compare efficacy of early blood 
transfusion 
Non-recipients 
(unknown) 
162 unknown Unknown unknown  
PHBP-recipients 
(unknown) 
84 unknown Unknown unknown PBRC: 426ml 
Sumida et al. 
(2000) (48) 
Chattanooga, TN, USA 
Hartford, CN, USA 
Cohort 
Full Text 
(Retrospective 
Civilian) 
analyse the effect of PHBP on 
physiologic parameters and 
outcomes 
Non-recipients 
(unknown) 
31 
(unknown) 
30.4 Unknown ISS: 27.8 
RTS: 7.0 
TRISS: 0.669 
 
PHBP-recipients 
(unknown) 
17 
(unknown) 
31.2 Unknown ISS: 28.0 
RTS: 6.3 
TRISS: 0.524 
“blood”: 711mL 
Kim et al. 
(2012) (37) 
Rochester, MN, USA 
Cohort 
Full Text 
(Retrospective 
Civilian) 
will delivery of pre-hospital 
plasma improve coagulopathy 
PBRC only 
(Transfers: 54%) 
50 
(60%) 
41 Penetrating: 9 (18%) ISS: 23 
TRISS: 0.66 
PRBC: 1u 
PBRC + Plasma 
(Transfers: 100%) 
9 
(100%) 
54 Penetrating: 3 (33%) ISS: 27 
TRISS: 0.24* 
PRBC: 2.5u 
Plasma: 2.1u 
Badjie et al 
(2013) (39) 
Rochester, MN, USA 
Cohort 
Abstract 
(Retrospective 
Civilian) 
to evaluate mortality rates of 
patients who received a 1:1 FFP: 
RBC ratio en-route 
PBRC:Plasma 2:1 
(unknown) 
79 
(unknown) 
Unknown but 
“comparable” 
Reasons for transport not stated 
by “comparable” 
unknown Up to 2u PRBC+2u Plasma+2u 
PRBC  OR 2u Plasma+4u PRBC 
PBRC:Plasma 1:1 
(unknown) 
79 
(unknown) 
unknown Up to 3u plasma + 3u PRBC 
PHBP-recipients 
(Transfers: 0%) 
66 
(61%) 
median 40 Unknown  Not specified 
Brown et al. 
(2015) (35-i) 
Pittsburgh, PA, USA 
Cohort 
Full Text 
(Retrospective 
Civilian) 
Is pre-trauma centre RBC 
transfusion associated with 
reduced mortality and early 
TIC? 
Non-recipients 
(Transfers: 4%) 
1365 
(67%) 
41 
(26-54) 
unknown ISS: 33 (22–41)  
PHBP-recipients 
(Transfers: 48%) 
50 
(64%) 
41 (28-52) unknown ISS: 37 (24–43) PRBC: 1.3 (1.0–2.3) 
Brown et al. 
(2015) (35-ii) 
Pittsburgh, PA, USA 
Matched Cohort 
Full Text 
(Retrospective 
Civilian) 
Is pre-trauma centre RBC 
transfusion associated with 
reduced mortality and TIC in a 
matched cohort? 
Non-recipients 
(Transfers: 24%) 
78 
(72%) 
37 (24–55) unknown ISS: 30 (23–43)  
PHBP-recipients 
(Transfers: 29%) 
35 
(60%) 
36 (28–52) unknown ISS: 34 (18–43) PRBC: 1.2 (1.0–2.0) 
Brown et al. 
(2015) (36-i) 
Pittsburgh, PA, USA 
Cohort 
Full Text 
(Retrospective 
Civilian) 
Is pre-trauma centre PBC 
transfusion associated with 
reduced 24h mortality, TIC, 
shock and Tx requirements in 
air medical transport 
Non-recipients 
(Transfers: 75%) 
480 
(67%) 
49 (31-68) Blunt: 395 (82%) 
Penetrating: 85 (18%) 
ISS: 17 (9-27)  
PHBP-recipients 
(Transfers: 68%) 
240 
(69%) 
49 (28-71.5) Blunt: 191 (80%) 
Penetrating: 49 (20%) 
ISS: 18 (10-29) PRBC: 300ml 
(IQR: 200-500) 
Brown et al. 
(2015) (36-ii) 
Pittsburgh, PA, USA 
Cohort 
Full Text 
(Retrospective 
Civilian) 
Is pre-trauma centre PBC 
transfusion associated with 
reduced 24h mortality, TIC, 
shock and Tx requirements in 
patients transported from scene 
Non-recipients 
(Transfers: 0%) 
142 
(68%) 
37 (25-65) Blunt: 98 (69%) 
Penetrating: 44 (31%) 
ISS: 22 (13-29)  
PHBP-recipients 
(Transfers: 0%) 
71 
(83%) 
42 (24-55) Blunt: 98 (69%) 
Penetrating: 44 (31%) 
ISS: 22 (10-34) PRBC: 300ml 
(IQR: 200-500) 
Wheeler et al. 
(2013) (57) 
Lebanon, NH, USA 
Case-Control 
Full Text 
identify factors associated with 
hypothermia 
Non-hypothermic 
(Transfers: 0%) 
647 
(68%) 
39 (SD: 19) unknown ISS: 16 (SD: 11) 
RTS: 7.34 (SD: 1.19) 
TRISS: 0.93 (SD: 0.16) 
PRBC given to 3% of subjects 
 
 
(Retrospective 
Civilian) 
 
Hypothermic (<35°C) 
(Transfers: 0%) 
60 
(68%) 
41 (SD: 20) unknown ISS: 26 (SD: 12) 
RTS: 5.86 (SD: 1.85) 
TRISS: 0.75 (SD: 0.29) 
Up to 3u PRBC given to 17% of 
subjects 
O'Reilly et al. 
(2014) (40) 
Afghanistan 
Matched Cohort 
Full Text 
(Retrospective 
Military) 
"PHBP will be associated with 
reduction in mortality" 
Non-recipients 97 
(100%) 
23 (21-28) Explosive: 48 (49%) 
GSW: 46 (47%) 
Blunt: 3 (3%) 
mISS: 16 (9-25) 
mNISS: 21 (14-34) 
 
PHBP-recipients 97 
(98%) 
24 (20-28) Explosive: 50 (52%) 
GSW: 46 (47%) 
Blunt: 1 (1%) 
mISS: 16 (9-25) 
mNISS: 22 (15-33) 
PRBC: 1u (IQR: 1-2) [R: 0-4] 
Plasma: 2u (IQR: 1-2) [R: 0-4] 
Smith et al. 
(2014) (46) 
Afghanistan 
Cohort 
Abstract 
(full data available) 
(Retrospective 
Military) 
Is PHBP receipt associated with 
reduced mortality or 
coagulopathy? 
Non-recipients 775 
(96.6%) 
median band: 17-
24 
Explosive: 423 (55%) 
GSW: 274 (35%) 
MVC: 46 (6%) 
Burn: 11 (1%) 
Other: 21 (3%) 
ISS: 18 (14-26) 
NISS: 25 (18-34) 
 
PHBP-recipients 272 
(98.5%) 
median band: 17-
24 
Explosive: 250 (92%) 
GSW: 19 (7%) 
MVC: 3 (1%) 
ISS: 26 (18-30) 
NISS: 41 (29-54) 
PBRC: 2u (IQR: 1-2) [R: 0-4] 
Plasma: 2u (IQR: 1-2) [R: 0-4] 
Gross et al. 
(2014) (56) 
Afghanistan 
Conference Poster 
(Retrospective 
Military) 
Not stated Non-recipients 54 
(unknown) 
25 (22-28) unknown unknown  
PHBP-recipients 66 
(unknown) 
25 (24-29) unknown unknown not specified 
mISS and mNISS: ISS and NISS derived from the military edition of the Abbreviated Injury Scale (2005)  
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Supplementary File 2: EMBASE Search Strategy 
 
1     (red blood cell$ or red cell$).mp. [mp=title, abstract, subject headings, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
(103973) 
2     (RBC$ or pRBC$ or PRC$ or RCC$).mp. [mp=title, abstract, subject headings, heading 
word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword] (56232) 
3     (blood product$ or blood component$ or whole blood).mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, 
device trade name, keyword] (68383) 
4     blood administrat$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] (256) 
5     (blood adj3 resuscitat$).mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (2799) 
6     (plasma adj3 resuscitat$).mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (1069) 
7     (freeze dried plasma or fresh frozen plasma or liquid plasma or thawed plasma or spray dried 
plasma or lyophili?ed plasma or FDP or FFP).mp. [mp=title, abstract, subject headings, heading 
word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword] (16810) 
8     (hemostatic resuscitat$ or haemostatic resuscitat$).mp. [mp=title, abstract, subject headings, 
heading word, drug trade name, original title, device manufacturer, drug manufacturer, device 
trade name, keyword] (133) 
9     damage control resuscitat$.mp. [mp=title, abstract, subject headings, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
(237) 
10     1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 (214180) 
11     (pre-hospital or prehospital or pre-trauma or pretrauma).mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, 
device trade name, keyword] (13713) 
12     (point of injury or point of wound$).mp. [mp=title, abstract, subject headings, heading word, 
drug trade name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword] (271) 
13     (on scene or en route or in transit or retrieval).mp. [mp=title, abstract, subject headings, 
heading word, drug trade name, original title, device manufacturer, drug manufacturer, device 
trade name, keyword] (69262) 
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14     out of hospital.mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] (9408) 
15     (air or helicopter$ or aviation or rotary wing).mp. [mp=title, abstract, subject headings, 
heading word, drug trade name, original title, device manufacturer, drug manufacturer, device 
trade name, keyword] (319881) 
16     paramedic$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] (21340) 
17     exp paramedical personnel/ (362883) 
18     exp emergency physician/ (6248) 
19     (emergency adj3 doctor$).mp. [mp=title, abstract, subject headings, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
(1185) 
20     first aid.mp. or exp first aid/ (11842) 
21     exp emergency treatment/ (175524) 
22     exp traffic accident/ (46473) 
23     (evacuation$ or field or battlefield or wartime or military or casualt$).mp. [mp=title, abstract, 
subject headings, heading word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] (642507) 
24     exp army/ (10233) 
25     (advanced trauma life support or ATLS).mp. [mp=title, abstract, subject headings, heading 
word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword] (1106) 
26     (basic trauma life support or BTLS).mp. [mp=title, abstract, subject headings, heading word, 
drug trade name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword] (28) 
27     11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 
(1581097) 
28     trauma.mp. or exp injury/ (1616710) 
29     injur$.mp. (1174622) 
30     (haemorrhag$ or hemorrhag$).mp. [mp=title, abstract, subject headings, heading word, 
drug trade name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword] (362963) 
31     exp bleeding/ or bleed$.mp. (653782) 
32     shock.mp. or hypovolemic shock/ or traumatic shock/ or hemorrhagic shock/ (232638) 
33     exp hypovolemia/ or hypovol$.mp. (14499) 
34     (blood adj2 loss).mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] (51109) 
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35     low blood pressure.mp. or exp hypotension/ (105125) 
36     hypotens$.mp. (133901) 
37     28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 (2675652) 
38     10 and 27 and 37 (6184) 
 
*************************** 
Supplementary File 3: Relevant excluded studies  
Authors Year Publication / Meeting / Source 
Volu
me Issue Page(s) Reason for exclusion 
Hall et al. 1990 Annals of Emergency Medicine 19  49 Unavailable 
Brown et al. 
1995 
Society for Academic Emergency 
Medicine 
Conference 
Proceedings 
16 Unavailable 
Ciraulo et al. 1998 Critical Care Medicine 26 (Suppl 1) 51A Abstract of included paper 
Tilney et al. 2007 Annals of Emergency Medicine 50 3 (Suppl) S92 Case series - no clinical outcomes 
Calderbank et al. 2011 Emergency Medicine Journal 28 10 882-883 Case series - no clinical outcomes 
Bates et al. 
2012 
Air Medical Journal 31 6 260 Study size and outcomes not 
quantified 
Edgar et al. 2012 British Journal of Surgery 99 Suppl 6 12 Abstract of excluded paper 
Chin et al. 2013 Journal of Surgical Research 179 2 337 Abstract of included paper 
Holcomb et al. 2013 Circulation 128 22  Abstract of included paper 
Lockey et al. 2013 Transfusion 53 Suppl 1 17S-22S Case series - no clinical outcomes 
Morrison et al. 2013 Annals of Surgery 257 2 330-334 Bundle of care study 
O'Reilly et al. 2013 Royal Society of Medicine: Military Section Colt Foundation Prize Meeting Abstract of included paper 
Edgar et al. 
2014 
Journal of the Royal Naval Medical 
Service 
100 1 12-Jul Bundle of care study 
Jenkins et al. 2014 Shock 41 Suppl 1 84-89 Case series - no clinical outcomes 
Spiess et al. 
2014 
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/ 
NCT02303964 
Ongoing study - PUPFTH 
Wolf et al. 2014 Transfusion Medicine 24 s2 24 Case series – no clinical outcomes 
Bebarta 2015 Critical Care Medicine 42 12 (Suppl) e146 Case series - no clinical outcomes 
Brown et al. 2015 Prehospital Emergency Care 19 3 343-350 RCT in progress - PAMPER 
Chapman et al. 2015 Shock 44 (Suppl 1) 63-70 RCT in progress - COMBAT 
Chin et al. 2015 Surgery 157 1 10-19 RCT in progress - COMBAT 
Holcomb et al. 2015 Prehospital Emergency Care 19 1 1-9 Bundle of care study 
Holcomb et al. 
2015 
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/ 
NCT02272465 
Cohort study in progress - PROHS 
Midwinter et al. 2015 National Institue for Health Research:  
Efficacy and Mechanistic Evaluation 
Programme 
http://www.nets.nihr.ac.uk/__data/as
sets/pdf_file/0018/139212/EME_fund
ing_outcomes_table_Feb-15.pdf 
RCT in setup - RePHILL 
Moore et al. 2015 Shock 41 Suppl 1 35-38 RCT in progress - COMBAT 
Stubbs et al. 2015 Transfusion 55 8 1830-37 Duplicate data from Kim et al. (2012) 
 
Supplementary File 4 – Interventions and Differences 
 
Table 1: Studies reporting 30-day or long-term mortality 
Author Year PHBP 
recipients / 
total study size 
Intervention Differences between groups 
(PHBP-recipients vs. non-recipients) 
Dalton 1993 (12) 112 PBRC:416ml [R:100-
1250] 
N/A 
Berns 1998 (59) 94 “average” 2u PRBC3 N/A 
Price 1999 (49) 84/246 
 
PRBC: 626ml ±262ml Pre-hospital crystalloid: 3.0L vs. 0.8L  
Tracheal intubation: 47% vs. 34% 
In-hospital blood products: 1.4L vs. 1L 
Barkana 1999 (14) 40 PRBC: 1u (1-2u) [R:1-
4u] 
N/A 
Sumida 2000 (48) 17/48 mean 710.7ml "blood" Flight time 33min vs. 12 min 
Higgins 2012 (55) 45 PBRC: 1.4u ± 0.23u N/A 
Badjie 2013 (39) 79/158 3u TP+3u PRBC vs. 
2u PRBC+2u TP+2u 
PBRC 
None reported 
Glassberg 2013 (67) 10 1.5u LP (1-2u) 
(PRBC not reported) 
N/A 
Mena-
Mundoz 
2013 (74) 1441 Up to 2u PBRC N/A 
Weaver 2013 (23) 50 mean 2.8u PBRC N/A 
Bodnar 2014 (50) 71 1.8u PBRC ±0.74u N/A 
O’Reilly 2014 (41) 310 PBRC: 2u (1-2) [R:0-4] 
Plasma: 2u (1-2) [R:0-4] 
N/A 
O’Reilly 2014 (40) 97/194 PBRC: 1u (1-2) [R:0-4] 
Plasma: 2u (1-2) [R: 0-4] 
Advanced Airway: 20% vs. 9% 
Tranexamic acid receipt: 23% vs. 0% 
Pre-hospital time: 68min vs. 110min 
In-hospital transfusion: 2u PBRC + 2u FFP vs. 
none 
Powell-
Dunford 
2014 (54) 61 PBRC: 1u (1-1) [R:1-2]  
Plasma: 0u (0-0) [R :0-1] 
N/A 
Smith 2014 (46) 272/1047 PBRC: 2u (1-2) [R: 0-4] 
Plasma: 2u (1-2) [R: 0-4] 
Explosive injuries: 92% vs. 55% 
GSW: 7% vs 35% 
median NISS: 41 vs 25. 
Tranexamic acid receipt: 21% v. 0.5%. 
In-hospital tx: 15 u PRBC+15 u plasma vs. 4u 
+ 4u 
Brown 2015 
(35-i) 
50/1365 PRBC: 1.3u (1–2) Secondary transfer: 48% vs. 4% 
Pre-hospital crystalloid: 2.6L vs. 1.0L 
In-hospital tx: 15u PRBC + 3u plasma vs. 7u + 
3u 
Brown 2015 
(35-ii) 
35/113 PRBC: 1.2u (1–2) In-hospital tx: 14u PRBC vs. 8u PRBC 
Brown 2015 
(36-i) 
240/720 PRBC: 300ml (200-
500ml) 
Emergency surgery: 48% vs. 28% 
Brown 2015 
(36-ii) 
71/213 PRBC: 300ml (200-
500ml) 
None 
Sunde 2015 
(53) 
16 LP: 200ml (R: 100-
200ml) 
N/A 
 
 
  
Supplementary Table 2: Studies reporting pre-hospital mortality 
Author Year PHBP 
recipients / 
total study size 
Intervention1 Differences between groups 
(PHBP-recipients vs. non-recipients) 
Prause 1999 (52) 26 not specified N/A 
Chew 2013 (51) 59 PBRC: 2u (2-4u) N/A 
Sherren 2013 (25) 147 PBRC: 3u (1-6u) N/A 
Weaver 2013 (23) 50 PRBC: mean 2.8u N/A 
Bodnar 2014 (50) 71 PBRC: mean 1.8u 
(±0.7u) 
N/A 
Sunde 2015 (53) 16 LP: 200ml (R: 100-
200ml) 
N/A 
 
Supplementary Table 3: Studies reporting 24h mortality 
Author Year PHBP 
recipients / 
total study 
size 
Intervention1 Differences between groups 
(PHBP-recipients vs. non-recipients) 
Kim 2012 (37) 59 PRBC : 2.5u vs. 1u 
Plasma: 2.1u vs. 0u 
Warfarin: 22% vs. 2%  
Prehospital crystalloid:2.4L vs. 1.6L 
Pre-transfusion INR: 2.6 vs. 1.5 
In-hospital PRBC: 12.7u  vs. 11.4u 
In-hospital plasma: 11.5u vs. 5.5u 
In-hospital crystalloid: 6.3L vs. 16.4L 
Brown 2015 (35-i) 
As 30-day mortality table Brown 2015 (35-ii) 
Brown 2015 (36-i) 
 
Supplementary File 5 – Risk of Bias Assessments 
Risk of Bias in Case Series 
 Design Cases Intervention Outcome Follow-up 
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Quality of 
Evidence 
Dalton (1993) (12) - + + ? + - + ? - + + + Very Low 
Berns and Zietlow (1998) (59) + + ? + - - + - - + + - Very Low 
Barkana et al (1999) (14) - + + + + - + + - + + + Very Low 
Prause et al (1999) (52) - - + ? - + + ? - - + - Very Low 
Badjie et al (2012) (38) - + - + - - + - - -  - Very Low 
Higgins et al (2012) (55) - - ? + - + + + - + + + Very Low 
Chew et al (2013) (51) + - + + + - + + - - + - Very Low 
Mena-Mundoz (2013) (74) - - - + + + + - - - + - Very Low 
Sherren & Burns (2013) (25) - - + + + + + - - - + - Very Low 
Malsby et al (2013) (15) - + + ? - - + - - - - + Very Low 
Glassberg et al (2013) (67) + + + + - + + + - + + + Very Low 
Weaver et al (2013) (23) - + + + + + + + - + + + Very Low 
Bodnar et al (2014) (50) + + + + + + + + - + + + Very Low 
O’Reilly et al (2014) (41) + + + + + + + + - + + + Very Low 
Chen (2014) (74) + + ? + + + + ? - - ? + Very Low 
Powell-Dunford (2014) (54) - + + ? + - + - - - - - Very Low 
Sunde et al (2015) (53) + + + + - + + + - + + + Very Low 
1Treatment ascertainment assumed to be satisfactory due to haemovigilance requirements 
 
 
 
  
Risk of Bias in Comparative Studies (Newcastle-Ottawa Scale) 
 Cohorts  Controls for  Follow-up  
Study 
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Quality of 
Evidence 
Price et al (1999) (49) + - + + + + + - + Very Low 
Sumida et al (2000) (48) + + + - -  + - + Very Low 
Kim et al (2012) (37) - - + + - - + + + Very Low 
Badjie et al (2013) (39) - - + + - - + + + Very Low 
Wheeler et al (2013) (57) + + + - - - + + + Very Low 
Gross et al (2014) (56) + + + - - - + + + Very Low 
O’Reilly et al (2014) (40) - - + + + - + + + Very Low 
Smith et al (2014) (46) + - + + + + + + + Very Low 
Brown et al (2015) (35) + + + + + + + + + Low 
Brown et al (2015) (36) + + + + + + + + + Low 
1Treatment ascertainment assumed to be satisfactory due to haemovigilance requirements 
2Statistical correction or case matching 
 
Supplementary Table 6: Ongoing Prospective Trials and Cohort Studies 
Study Design Status Authors Year Journal Vol Issue Pages/Article 
Control Of Major 
Bleeding After Trauma 
(COMBAT) 
Pilot RCT Recruiting Moore 
et al. 
2015 Shock 41 Suppl 
1 
35-38 
Prehospital Air Medical 
Plasma trial (PAMPER) 
RCT Recruiting Brown et al. 2015 Prehospital 
Emergency Care 
19 3 343-50 
Prehospital Use of 
Plasma for Traumatic 
Hemorrhage (PUPTH) 
RCT Recruiting Reynolds 
et al. 
2015 Trials 16 1 321 
Resuscitation with Pre-
HospItaL bLood 
products (RePHILL) 
RCT Funding and 
regulatory approvals 
obtained 
Midwinter 
et al. 
2015 http://www.nets.nihr.ac.uk/__data/assets/pdf_file/00
18/139212/EME_funding_outcomes_table_Feb-15.pdf 
Prehospital Resuscition 
On Helicopters Study 
(PROHS) 
Prospective 
cohort 
Recruiting Holcomb 
et al. 
2015 https://clinicaltrials.gov/ct2/show/NCT02272465 
 
 
